NEW YORK – Biotech company Bolt Biotherapeutics said last Thursday that it formally kicked off the Phase I trial of its investigational immunotherapy agent BDC-1001 in patients with HER2-expressing solid tumors.
NEW YORK – Biotech company Bolt Biotherapeutics said last Thursday that it formally kicked off the Phase I trial of its investigational immunotherapy agent BDC-1001 in patients with HER2-expressing solid tumors.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.